Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021

Sara Suliman; Puck T Pelzer; Moagi Shaku; Virginie Rozot; Simon C Mendelsohn

doi:10.1016/j.vaccine.2021.08.094

Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021

Vaccine. 2021 Dec 8;39(50):7223-7229. doi: 10.1016/j.vaccine.2021.08.094. Epub 2021 Sep 15.

Authors

Sara Suliman¹, Puck T Pelzer², Moagi Shaku³, Virginie Rozot⁴, Simon C Mendelsohn⁵

Affiliations

¹ Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; KNCV Tuberculosis Foundation, The Hague, the Netherlands.
³ Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA.
⁴ Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, Wernher and Beit South Building, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa.
⁵ Stop TB Partnership Working Group on New TB Vaccines, New York, NY, USA; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, Wernher and Beit South Building, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. Electronic address: simon.mendelsohn@uct.ac.za.

Abstract

The Global Forum on Tuberculosis (TB) Vaccines was held virtually from 20 to 22 April 2021, marking its 20^th anniversary. The Global Forum on TB Vaccines is the world's largest gathering of stakeholders striving to develop new vaccines to prevent TB. The program included more than 60 speakers in 11 scientific sessions, panel discussions, and workshops. It provided an overview of the state of the field, and an opportunity to share the latest research findings, as well as new and innovative approaches to TB vaccine research and development (R&D). This year, it was held against the backdrop of the COVID-19 pandemic and convened researchers, developers, funders, and other stakeholders remotely to discuss opportunities and challenges for TB vaccine R&D in these unprecedented times.

Keywords: BCG; COVID-19; Funding; Pandemic; Pipeline; Tuberculosis; Vaccine.

Publication types

Clinical Conference
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Humans
Pandemics
SARS-CoV-2
Tuberculosis Vaccines*
Tuberculosis* / prevention & control

Substances

Tuberculosis Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding